5PSQ-028 病例报告：恩替瑞尼对原发性中枢神经细胞瘤患者的抗肿瘤活性和毒性反应

{"title":"5PSQ-028 病例报告：恩替瑞尼对原发性中枢神经细胞瘤患者的抗肿瘤活性和毒性反应","authors":"M. Giraldez, L. Valdeolmillos, E. Mateo, C. Garcia Pastor, ME Rodriguez-Ruiz","doi":"10.1136/ejhpharm-2024-eahp.362","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":107680,"journal":{"name":"Section 5: Patient safety and quality assurance","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"5PSQ-028 Case report: antitumor activity and toxicities of entrectinib in a patient with a primary central neurocytoma\",\"authors\":\"M. Giraldez, L. Valdeolmillos, E. Mateo, C. Garcia Pastor, ME Rodriguez-Ruiz\",\"doi\":\"10.1136/ejhpharm-2024-eahp.362\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":107680,\"journal\":{\"name\":\"Section 5: Patient safety and quality assurance\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Section 5: Patient safety and quality assurance\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ejhpharm-2024-eahp.362\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Section 5: Patient safety and quality assurance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2024-eahp.362","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}